XNYSDNA
Market cap562mUSD
Jan 10, Last price
9.78USD
1D
-11.97%
1Q
33.42%
IPO
-97.99%
Name
Ginkgo Bioworks Holdings Inc
Chart & Performance
P/E
—
P/S
2.24
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
20.67%
Revenues
251m
-47.36%
Net income
-893m
L-57.58%
CFO
-296m
L+17.17%
Earnings
Jun 13, 2025
Profile
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
IPO date
Apr 19, 2021
Employees
1,292
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 251,455 -47.36% | 477,706 52.21% | |||
Cost of revenue | 1,019,651 | 2,686,658 | |||
Unusual Expense (Income) | |||||
NOPBT | (768,196) | (2,208,952) | |||
NOPBT Margin | |||||
Operating Taxes | (71) | (15,027) | |||
Tax Rate | |||||
NOPAT | (768,125) | (2,193,925) | |||
Net income | (892,869) -57.58% | (2,104,929) 15.02% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (23) | 98,322 | |||
BB yield | 0.00% | -3.46% | |||
| Debt | |||||
Debt current | 19,933 | 29,332 | |||
Long-term debt | 443,670 | 826,512 | |||
Deferred revenue | 158,062 | 174,767 | |||
Other long-term liabilities | 24,433 | 42,059 | |||
Net debt | (559,035) | (573,679) | |||
| Cash flow | |||||
Cash from operating activities | (295,500) | (252,198) | |||
CAPEX | (40,801) | (52,271) | |||
Cash from investing activities | (80,693) | (67,394) | |||
Cash from financing activities | (3,216) | 95,337 | |||
FCF | (449,814) | (2,743,745) | |||
| Balance | |||||
Cash | 944,073 | 1,315,792 | |||
Long term investments | 78,565 | 113,731 | |||
Excess cash | 1,010,065 | 1,405,638 | |||
Stockholders' equity | (5,288,845) | (4,400,101) | |||
Invested Capital | 6,810,260 | 6,795,792 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 48,610 | 41,996 | |||
Price | 67.60 0.00% | 67.60 -79.66% | |||
Market cap | 3,286,070 15.75% | 2,838,928 -74.89% | |||
EV | 2,727,035 | 2,265,249 | |||
EBITDA | (696,642) | (2,164,529) | |||
EV/EBITDA | |||||
Interest | 93 | 106 | |||
Interest/NOPBT | |||||